Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Zealand Pharma licenses Aventis rights to diabetes compound

Executive Summary

Biopharmaceutical company Zealand Pharma AS (therapeutics for diabetes, cardiac arrhythmia, and heart failure) licensed Aventis worldwide rights to its lead compound ZP10, a glucagon-like peptide-1 (GLP-1) receptor agonist in Phase I/IIa clinical trials to treat Type II diabetes.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • Marketing (Licensing)

Related Companies